Recent data indicates that retatrutide, a dual-action medication, may represent a significant improvement in size loss . This treatment combines the properties of a GLP-1 agonist and a GIP agonist , seemingly offering a enhanced outcome than current therapies . Study assessments have demonstrated promising outcomes, including significant declines i